These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 21278436)

  • 1. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
    Baselga J
    Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Zardavas D; Fumagalli D; Loi S
    Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
    Coughlin CM; Johnston DS; Strahs A; Burczynski ME; Bacus S; Hill J; Feingold JM; Zacharchuk C; Berkenblit A
    Breast Cancer Res Treat; 2010 Nov; 124(1):1-11. PubMed ID: 20803067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.
    Crowder RJ; Ellis MJ
    Breast Cancer Res; 2005; 7(5):212-4. PubMed ID: 16168140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.
    Bartlett JM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S86-95. PubMed ID: 21115427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the PI3K pathway play a role in basal breast cancer?
    Moulder SL
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S66-71. PubMed ID: 21115424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting endocrine resistance: is there a role for mTOR inhibition?
    Sheri A; Martin LA; Johnston S
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S79-85. PubMed ID: 21115426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer.
    Castaneda CA; Cortes-Funes H; Gomez HL; Ciruelos EM
    Cancer Metastasis Rev; 2010 Dec; 29(4):751-9. PubMed ID: 20922461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Targeting Ras-PI3K/mTOR pathway and the predictive biomarkers in endometrial cancer].
    Oda K
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1084-7. PubMed ID: 21772091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple signal pathways in obesity-associated cancer.
    Chen J
    Obes Rev; 2011 Dec; 12(12):1063-70. PubMed ID: 22093240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PI3K inhibitor].
    Yano S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Ohtsubo K; Yasumoto K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):23-6. PubMed ID: 21368457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [PI3K-AKT-mTOR pathway inhibitors].
    Cortot A; Armand JP; Soria JC
    Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
    Zhang J; Roberts TM; Shivdasani RA
    Gastroenterology; 2011 Jul; 141(1):50-61. PubMed ID: 21723986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
    Zhou Q; Lui VW; Yeo W
    Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the PI3K pathway: hope we can believe in?
    van der Heijden MS; Bernards R
    Clin Cancer Res; 2010 Jun; 16(12):3094-9. PubMed ID: 20400520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
    Abraham J
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):51-68. PubMed ID: 25306975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
    Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mTOR signaling in lung cancer.
    Marinov M; Fischer B; Arcaro A
    Crit Rev Oncol Hematol; 2007 Aug; 63(2):172-82. PubMed ID: 17540577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope.
    De P; Miskimins K; Dey N; Leyland-Jones B
    Cancer Treat Rev; 2013 Aug; 39(5):403-12. PubMed ID: 23352077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.